Randomized Controlled Trial

. 2022 Nov 18;48(6):1263-1272.

doi: 10.1093/schbul/sbac065.

N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms

Erica Neill^{1

2

3}, Susan L Rossell^{1

2}, Caitlin Yolland^{1

2}, Denny Meyer¹, Cherrie Galletly^{4

5

6}, Anthony Harris^{7

8}, Dan Siskind^{9

10}, Michael Berk^{11

12

13}, Kiymet Bozaoglu^{14

15}, Frances Dark^{9

10}, Olivia M Dean^{11

12}, Paul S Francis¹⁶, Dennis Liu^{4

6}, Andrea Phillipou¹, Jerome Sarris^{12

17

18}, David J Castle^{1

2

3}

Affiliations

¹ Centre for Mental Health, Faculty of Health, Arts & Design, Swinburne University of Technology, Melbourne, Australia.
² Department of Mental Health, St Vincent's Hospital, Melbourne, Australia.
³ Department of Psychiatry, University of Melbourne, Melbourne, Australia.
⁴ Department of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.
⁵ Ramsay Health Care (SA) Mental Health, Adelaide, Australia.
⁶ Northern Adelaide Local Health Network, Adelaide, Australia.
⁷ Specialty of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia.
⁸ Westmead Institute for Medical Research, Westmead, NSW 2145, Australia.
⁹ Metro South Addiction and Mental Health Service, Brisbane, Australia.
¹⁰ UQ School of Clinical Medicine, Brisbane, Australia.
¹¹ Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
¹² Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Melbourne, Australia.
¹³ Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia.
¹⁴ Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
¹⁵ Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Melbourne, Australia.
¹⁶ School of Life and Environmental Sciences, Faculty of Science, Engineering and Built Environment, Deakin University, Waurn Ponds, VIC, Australia.
¹⁷ NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia.
¹⁸ Professional Unit, The Melbourne Clinic, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia.

PMID: 35857752
PMCID: PMC9673271
DOI: 10.1093/schbul/sbac065

Randomized Controlled Trial

N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms

Erica Neill et al. Schizophr Bull. 2022.

. 2022 Nov 18;48(6):1263-1272.

doi: 10.1093/schbul/sbac065.

Authors

Affiliations

¹ Centre for Mental Health, Faculty of Health, Arts & Design, Swinburne University of Technology, Melbourne, Australia.
² Department of Mental Health, St Vincent's Hospital, Melbourne, Australia.
³ Department of Psychiatry, University of Melbourne, Melbourne, Australia.
⁴ Department of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia.
⁵ Ramsay Health Care (SA) Mental Health, Adelaide, Australia.
⁶ Northern Adelaide Local Health Network, Adelaide, Australia.
⁷ Specialty of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia.
⁸ Westmead Institute for Medical Research, Westmead, NSW 2145, Australia.
⁹ Metro South Addiction and Mental Health Service, Brisbane, Australia.
¹⁰ UQ School of Clinical Medicine, Brisbane, Australia.
¹¹ Deakin University, IMPACT-the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
¹² Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Melbourne, Australia.
¹³ Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia.
¹⁴ Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
¹⁵ Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Melbourne, Australia.
¹⁶ School of Life and Environmental Sciences, Faculty of Science, Engineering and Built Environment, Deakin University, Waurn Ponds, VIC, Australia.
¹⁷ NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia.
¹⁸ Professional Unit, The Melbourne Clinic, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia.

PMID: 35857752
PMCID: PMC9673271
DOI: 10.1093/schbul/sbac065

Abstract

Background and hypothesis: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet a significant proportion of individuals on clozapine continue to experience disabling symptoms, despite being treated with an adequate dose. There is a need for adjunct treatments to augment clozapine, notably for negative and cognitive symptoms. One such potential agent is the glutathione precursor N-acetylcysteine (NAC).

Study design: A randomized double-blind, multi-center, placebo-controlled trial for clozapine patients with enduring psychotic symptoms (n = 84) was undertaken to investigate the efficacy of adjunctive NAC (2 g daily) for negative symptoms, cognition and quality of life (QoL). Efficacy was assessed at 8, 24, and 52 weeks.

Study results: NAC did not significantly improve negative symptoms (P = .62), overall cognition (P = .71) or quality of life (Manchester quality of life: P = .11; Assessment of quality of life: P = .57) at any time point over a 1-year period of treatment. There were no differences in reported side effects between the groups (P = .26).

Conclusions: NAC did not significantly improve schizophrenia symptoms, cognition, or quality of life in treatment-resistant patients taking clozapine. This trial was registered with "Australian and New Zealand Clinical Trials" on the 30 May, 2016 (Registration Number: ACTRN12615001273572).

Keywords: cognition; depression; mental disorders; mental illness; neuroscience; psychiatry; quality of life.

PubMed Disclaimer

Figures

**Figure 2.**
PANSS negative scores at each assessment.

See this image and copyright information in PMC

References

1. Lally J, MacCabe JH.. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169–179. - PubMed
1. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394(10202):939–951. - PMC - PubMed
1. Sinkeviciute I, Begemann M, Prikken M, et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. NPJ Schizophr. 2018;4(1):1–14. - PMC - PubMed
1. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229. - PMC - PubMed
1. Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2021;220(3):1–6. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Associated data

ANZCTR/ACTRN12615001273572

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms

Affiliations

N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Medical